C
Chester R. Cooper
Researcher at Youngstown State University
Publications - 43
Citations - 2159
Chester R. Cooper is an academic researcher from Youngstown State University. The author has contributed to research in topics: Penicillium marneffei & Dimorphic fungus. The author has an hindex of 22, co-authored 43 publications receiving 1994 citations. Previous affiliations of Chester R. Cooper include University of Texas at Austin & Albany Medical College.
Papers
More filters
Journal ArticleDOI
Penicillium marneffei Infection and Recent Advances in the Epidemiology and Molecular Biology Aspects
TL;DR: Penicillium marneffei infection is an important emerging public health problem, especially among patients infected with human immunodeficiency virus in the areas of endemicity in southeast Asia, India, and China, and the natural history and mode of transmission of the organism remain unclear.
Journal ArticleDOI
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.
Ana Espinel-Ingroff,Marilyn S. Bartlett,Raleigh A. Bowden,N. X. Chin,Chester R. Cooper,A. Fothergill,Michael R. McGinnis,P. Menezes,Shawn A. Messer,P. W. Nelson,Frank C. Odds,L. Pasarell,Joanne Peter,Michael A. Pfaller,John H. Rex,Michael G. Rinaldi,G. S. Shankland,Thomas J. Walsh,Irene Weitzman +18 more
TL;DR: The overall optimal testing conditions identified were determination of colorimetric MICs after 48 to 72 h of incubation with an inoculum density of approximately 10(4) CFU/ml, proposed as guidelines for a reference broth microdilution method.
Journal ArticleDOI
Detection of amphotericin B-resistant Candida isolates in a broth-based system.
TL;DR: Antibiotic Medium 3 broth buffered to pH 5 or pH 7 produced superior results and readily identified a series of resistant isolates.
Journal ArticleDOI
Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens.
Khuanchai Supparatpinyo,Kenrad E. Nelson,W. G. Merz,B. J. Breslin,Chester R. Cooper,Chantana Kamwan,Thira Sirisanthana +6 more
TL;DR: Since at least 12 patients who responded to initial therapy relapsed within 6 months regardless of initial antifungal therapy, maintenance oral therapy with itraconazole or ketoconazole should be considered to be the drug of first choice in the treatment of mild to moderately severe P. marneffei infection.
Journal ArticleDOI
In vitro evaluation of voriconazole against some clinically important fungi.
Michael R. McGinnis,L. Pasarell,Deanna A. Sutton,Annette W. Fothergill,Chester R. Cooper,Michael G. Rinaldi +5 more
TL;DR: Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory Standards tentative standards against the dimorphic fungi and several opportunistic molds and yeasts.